2024
Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy
Contieri R, Tan W, Grajales V, Hensley P, Martini A, Bree K, Myers A, Nogueras‐Gonzalez G, Navai N, Dinney C, Guo C, Kamat A. Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU International 2024, 133: 733-741. PMID: 38374533, DOI: 10.1111/bju.16293.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerImmediate radical cystectomyCancer-specific survivalMetastasis-free survivalProgression-free survivalT1 substagingOverall survivalRadical cystectomyPathology reportsBladder cancerHigh-grade non-muscle-invasive bladder cancerPatients treated with bacillus Calmette-GuerinAssociated with poor progression-free survivalInstitutional review board-approved retrospective studyPatients treated with BCGPoor progression-free survivalLamina propriaAssociated with upstagingBCG-treated patientsCalculate overall survivalTreated with BCGKaplan-Meier methodHigh-grade patientsMultivariate Cox modelInvasive characteristics
2023
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile
Grajales V, Contieri R, Tan W, Flores M, Schultz M, Pinochet R, Bustamante A, Kamat A, Fernández M. Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile. Bladder Cancer 2023, 9: 327-334. PMID: 38994240, PMCID: PMC11165921, DOI: 10.3233/blc-230047.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBacillus Calmette-GuerinBacillus Calmette-Guerin treatmentHR-NMIBC patientsInvasive bladder cancerOncological outcomesHigh riskBladder cancerHigh-risk non-muscle invasive bladder cancerPatients treated with bacillus Calmette-GuerinAdjuvant bacillus Calmette-GuerinBacillus Calmette-Guerin instillationsFull doseFD groupMultivariate Cox regression modelCalculate survival estimatesReduced-dose regimensMedian follow-upRecurrence free rateKaplan-Meier methodReduced toxicity profileCox regression modelsHR-NMIBCStratify patientsRetrospective studyOncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, Lee B, Navai N, Dinney C, Kamat A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 2023, 6: 590-596. PMID: 37558542, DOI: 10.1016/j.euo.2023.07.012.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerCancer-specific mortalityBacillus Calmette-GuerinHigh-grade recurrenceHigh-risk non-muscle-invasive bladder cancerOverall survivalBladder cancerEuropean Urological AssociationOncological outcomesNo significant differenceEarly RCPatients treated with bacillus Calmette-GuerinTreated with bacillus Calmette-GuerinNon-muscle invasive bladder cancerIntravesical BCGContemporary cohort of patientsCancer-specific mortality ratesProgression rateBacillus Calmette-Guerin groupEarly radical cystectomyMedian follow-upInvasive bladder cancerSignificant differenceCohort of patientsEarly surgical removalA0607 T1 substaging is associated with worse oncological outcomes for patients treated with Bacillus Calmette-Guerin or immediate radical cystectomy
Contieri R, Tan W, Grajales V, Bree K, Hensley P, Guo C, Navai N, Dinney C, Kamat A. A0607 T1 substaging is associated with worse oncological outcomes for patients treated with Bacillus Calmette-Guerin or immediate radical cystectomy. European Urology 2023, 83: s865. DOI: 10.1016/s0302-2838(23)00653-x.Peer-Reviewed Original ResearchPatients treated with bacillus Calmette-GuerinAssociated with worse oncologic outcomesT1 substagingOncological outcomesRadical cystectomy